Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

Ll-37

Ll-37 MolecularFormula | C205H340N60O53 / MolecularWeight | 4493 / IUPACName | (4S)-5-[[(2S)-6-amino-1-[[(2S,3S)-1-[[2-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-6-amino-1-[[(2

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

Ll-37

MolecularFormulaC205H340N60O53
MolecularWeight4493
IUPACName(4S)-5-[[(2S)-6-amino-1-[[(2S,3S)-1-[[2-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S)-1-[[(2S)-1-[(2S)-2-[[(2S)-5-carbamimidamido-1-[[(2S,3R)-1-[[(2S)-4-carboxy-1-[[(1S)-1-carboxy-2-hydroxyethyl]amino]-1-oxobutan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-1-oxohexan-2-yl]amino]-2-oxoethyl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-4-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-amino-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-carboxypropanoyl]amino]-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]hexanoyl]amino]-3-hydroxypropanoyl]amino]hexanoyl]amino]-5-oxopentanoic acid
  • LL-37
  • ropocamptide
  • Cap-18
  • cathelicidin LL-37
  • CAP18
  • Antibacterial peptide LL-37
  • antimicrobial peptide LL-37
  • LL-37 antibacterial peptide
  • FA-LL-37
  • RefChem:153838
  • LL-37 antiviral peptide
  • ROPOCAMPTIDE [INN]
  • UNII-3DD771JO2H
  • CAS001
  • Antimicrobial Peptide, Human LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES
  • PROTEIN CAP 18 (RABBIT CATIONIC ANTIMICROBIAL 37-AMINO ACID FRAGMENT)
  • LEU-LEU-GLY-ASP-PHE-PHE-ARG-LYS-SER-LYS-GLU-LYS-ILE-GLY-LYS-GLU-PHE-LYS-ARG-ILE-VAL-GLN-ARG-ILE-LYS-ASP-PHE-LEU-ARG-ASN-LEU-VAL-PRO-ARG-THR-GLU-SER
  • antibacterial protein LL-37
  • L-SERINE, L-LEUCYL-L-LEUCYLGLYCYL-L-.ALPHA.-ASPARTYL-L-PHENYLALANYL-L-PHENYLALANYL-L-ARGINYL-L-LYSYL-L-SERYL-L-LYSYL-L-.ALPHA.-GLUTAMYL-L-LYSYL-L-ISOLEUCYLGLYCYL-L-LYSYL-L-.ALPHA.-GLUTAMYL-L-PHENYLALANYL-L-LYSYL-L-ARGINYL-L-ISOLEUCYL-L-VALYL-L-GLUTAMINYL-L-ARGINYL-L-ISOLEUCYL-L-LYSYL-L-.ALPHA.-ASPARTYL-L-PHENYLALANYL-L-LEUCYL-L-ARGINYL-L-ASPARAGINYL-L-LEUCYL-L-VALYL-L-PROLYL-L-ARGINYL-L-THREONYL-L-.ALPHA.-GLUTAMYL-
  • L-SERINE, L-LEUCYL-L-LEUCYLGLYCYL-L-ALPHA-ASPARTYL-L-PHENYLALANYL-L-PHENYLALANYL-L-ARGINYL-L-LYSYL-L-SERYL-L-LYSYL-L-ALPHA-GLUTAMYL-L-LYSYL-L-ISOLEUCYLGLYCYL-L-LYSYL-L-ALPHA-GLUTAMYL-L-PHENYLALANYL-L-LYSYL-L-ARGINYL-L-ISOLEUCYL-L-VALYL-L-GLUTAMINYL-L-ARGINYL-L-ISOLEUCYL-L-LYSYL-L-ALPHA-ASPARTYL-L-PHENYLALANYL-L-LEUCYL-L-ARGINYL-L-ASPARAGINYL-L-LEUCYL-L-VALYL-L-PROLYL-L-ARGINYL-L-THREONYL-L-ALPHA-GLUTAMYL-
  • Cathelicidin
  • 154947-66-7
  • LL 37
  • Cathelicidin LL 37
  • Bac4
  • hCAP 18
  • All38 peptide
  • LL-37(human)
  • LL-37 (Human)
  • LL-37/hCAP18
  • CAP18,
  • CHEMBL530345
  • SCHEMBL29350781
  • EX-A7429A
  • Cathelicidin antimicrobial peptide 18
  • AKOS024458536
  • RS-2000
  • DA-54959
  • FL110043
  • LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

Research context

Read sources and limitations before applying a claim.

for sale ll-37 research peptide

Methodologically, published studies frequently emphasize rigorous controls and validated assays to isolate peptide-specific effects. When LL-37 is combined with complementary research tools, investigators often test for additivity or pathway selectivity. Any observed changes are reported as laboratory findings rather than clinical recommendations.

Source: puretestedpeptides.com ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →